Fig. 3
From: The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo
The combination effect of DMAMCL with VCR or Epirubicin in RMS cells in vitro. a RMS cell lines were treated with VCR for 72 h. Cell survival was evaluated by MTS. Each data point represents the mean, SD of triplicate wells. b RMS cell lines were treated with Epirubicin for 72 h. Cell survival was evaluated by MTS. Each data point represents the mean, SD of triplicate wells. c RH18, RH30 and RH41 cells were treated with DMAMCL and VCR at different concentration in combination for 72 h. Cell survival was evaluated by MTS. Each data point represents the mean, SD of triplicate wells. The combination study was value by CI. CI < 1 indicates synergism, CI = 1 reflects an additive effect, and CI > 1 indicates drug antagonism. d RH18, RH30 and RH41 cells were treated with DMAMCL and VCR at different concentration in combination from 0 h to 72 h. Cell confluency(%) was calculated using Incucyte Zoom software by phase-contrast images. Each data point represents triplicate wells. e The pictures of RH18, RH30 and RH41 cells were treated with DMAMCL and VCR either alone or in combination for 72 h. f RH18, RH30 and RH41 cells were treated with DMAMCL and Epirubicin at different concentration in combination for 72 h. Cell survival was evaluated by MTS. Each data point represents the mean, SD of triplicate wells. The combination study was value by CI. g RH18, RH30 and RH41 cells were treated with DMAMCL and Epirubicin at different concentration in combination from 0 h to 72 h. Cell confluency(%) was calculated using Incucyte Zoom software by phase-contrast images. Each data point represents triplicate wells. h The pictures of RH18, RH30 and RH41 cells were treated with DMAMCL and Epirubicin either alone or in combination for 72 h